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Manufacturing processes for autologous cell therapy need to reproducibly generate in specification (quality and
quantity) clinical product. However, patient variability prevents the level of control of cell input material that
could be achieved in a cell line or allogeneic-based process. We have applied literature data on bone mar-
rowderived mesenchymal stromal cells variability to estimate probability distributions for stem cell yields
given underlying truncated normal distributions in total nucleated cell concentration, stem cell percentage and
plausible aspirate volumes. Monte Carlo simulation identified potential variability in harvested stem cell num-
ber in excess of an order of magnitude. The source material variability was used to identify the proportion of
donor manufacturing runs that would achieve a target yield specification of 2E7 cells in a fixed time window
with given proliferative rates and different aspirate volumes. A rapid, screening, development approach was
undertaken to assess culture materials and process parameters (T-flask surface, medium, feed schedule) to
specify a protocol with identified proliferative rate and a consequent model-based target aspirate volume.
Finally, four engineering runs of the candidate process were conducted and a range of relevant quality parame-
ters measured including expression of markers CD105, CD73, CD44, CD45, CD34, CD11b, CD19, HLA-DR, CD146
(melanoma cell adhesion molecule), CD106 (vascular cell adhesion molecule) and SSEA-4, specific metabolic
activity and vascular endothelial growth factor secretion, and osteogenic differentiation potential. Our
approach of using estimated distributions from publicly available information provides a route for data-poor
earl- stage developers to plan manufacture with defined risk based on rational assumptions; furthermore, the
models produced by such assumptions can be used to evaluate candidate processes, and can be incrementally
improved with accumulating distribution understanding or subdivision by new process variables.
© 2020 International Society for Cell and Gene Therapy. Published by Elsevier Inc. This is an open access article
under the CC BY license. (http://creativecommons.org/licenses/by/4.0/)Keywords:
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mesenchymal stromal cells (MSCs) are a cell type with a wide
range of potential therapeutic applications. Early activity was domi-
nated by orthopedic targets, but significant clinical activity has devel-
oped in tissue repair, such as cardiac, and across immunomodulatory
targets, such as multiple sclerosis and aging frailty. In addition to act-
ing through direct engraftment, MSCs are considered a potent thera-
peutic for modulating disease environments through a complex
bioactive secretome with anti-inflammatory and immunomodulatoryproperties that interacts beneficially with endogenous repair path-
ways [1]. MSCs have potential in the treatment of several clinically
challenging and hard-to-heal orthopedic indications [2,3]. As a result,
a first generation of MSC-containing products (collectively termed
“cellular bone matrices”) have achieved clinical uptake despite being
crudely prepared donor extracts with supply limitations (being har-
vested from cadavers), variable results and inconclusive clinical out-
comes [4]. More advanced orthopedic products involve in vitro
expansion of the human bone marrow mesenchymal stromal cells
(hBM-MSCs) before combination with a tissue scaffold to ensure that
post-implantation viability does not become compromised by anoikis
given the attachment dependence of the cells.
Cell supply issues can potentially be overcome by the pre-implanta-
tion expansion of MSCs, with an allogeneic “off-the-shelf” approach
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cells and the attractive regulatory and business model of a standardizable
off-the-shelf product [5]. However, there is some literature evidence that
allogeneic MSCs may elicit immune responses [6,7], and that rejection of
MSCs after differentiation may compromise clinical effectiveness [8].
These risksmay be reduced by expansion of the patient’s own cells to cre-
ate autologous ‘manufactured’ hBM-MSCs. However, such an approach
comes with its own challenges of variable starting material and poten-
tially more complex logistics of patient-specific processes and delivery
timings. The results of multiple clinical trials show that there have been
successes and failures with both approaches; the reasons for inconsis-
tency likely lie in the complexity of heterogenous non-comparable cell
populations between trials and inconsistent effects of processingmethod-
ologies including variable reagents and preservation methodologies [9].
Both allogeneic and autologous strategies are being actively pursued for
near-term clinical application.
As with the cell therapy field in general, the application of MSC-
based therapies has been challenged by the variability in processes
and products. Conventional pharmaceutical production has made
progress over the last decade through adoption of quality risk man-
agement strategies developed in other industries, codified in the
International Council for Harmonisation Quality Risk Management
document Q9 [10]. The ethos of these strategies is science-driven risk
assessment. However, although the principles are clear, the effective
application of quality risk management strategies for cell therapies
requires examples of appropriate tools that deal with the specific
issues of the field including variable biological input materials and
complex production processes [11]. A bioprocess for the manufacture
of a cell therapy needs to be sufficiently robust to the biological vari-
ability of the input material to consistently generate cells that meet
the required target product profile compatible with current Good
Manufacturing Practice. As with any cell therapy, the process is a key
determinant of the product, so decisions relating to bioprocess speci-
fication and control strategy must be quality risk-managed and sup-
ported with enough evidence to satisfy regulatory requirements (as
detailed by the International Council for Harmonisation of Technical
Requirements for Pharmaceuticals for Human Use in quality guide-
lines Q8/9).
As noted above, the autologous approach is complicated by signif-
icant donor variability [12]. The issue is further compounded in spe-
cific patient groups, such as the elderly or those with diabetes, owing
to an impaired in vivo niche for BM-MSCs resulting in fewer isolatable
BM-MSCs per milliliter bone marrow aspirate and with potential
qualitative impairment compared with healthy individuals [13]. Cell
therapy manufacturers must manage potential biological variability,
or systematic underperformance of autologous cells from the target
population with qualitative and quantitative hBM-MSC impairment
to avoid unquantified batch failure risk.
Bone marrow aspiration is generally regarded as a safe procedure,
however, there are complex and potentially conflicting drivers for
specifying aspiration volume for process input material. Excessive
aspiration may increase procedural pain [14], whereas insufficient
aspiration risks batch failure if not enough BM-MSC yield is achieved
post-expansion. Prolonged culture time (consequent on low aspira-
tion cell numbers) elevates risks like microbial contamination during
feeding operations, phenotypic drift and commercial risks relating to
manufacturing facility throughput and cost of goods. Specification of
aspiration volume is further challenged because bone marrow aspira-
tion is a manual process, lacking standardization with respect to
materials or sub-processes used. Simple factors like draw volume
and syringe volume are reported to influence initial BM-MSC yield
per milliliter, with greater draw volumes correlating with lower BM-
MSC yield per draw, as the aspirate becomes contaminated with
peripheral blood [15]. Alongside biological factors like disease state
or patient age, process factors including shipping conditions and
duration can also result in cell losses post-isolation [16].This article details the use of a Monte Carlo model to evaluate the
effect of variability in BM-MSC isolation from bone marrow aspira-
tion on process outcomes. The model was used to develop a
manufacturing framework to manage this variability, increasing the
speed and likelihood that a robust manufacturing process would be
defined with low risk of batch failure and accommodating logistical
process constraints (such as manufacture time). The derived isolation
and expansion processes were demonstrated using hBM-MSCs iso-
lated from healthy donors to confirm the validity of the approach.
Ultimately, our model is intended to be adjustable to account for any
observed impairment of BM-MSC yield and quality from specific
patient populations, for well-defined manufacturing and logistical
strategies, to maximizing the probability of obtaining a cell therapy
product suitable for clinical use from a precious autologous donation.
Methods
RoosterBio hBM-MSC culture
A cryovial containing cryopreserved RoosterBio hBM-MSCs (Roos-
terBio, Inc., Frederick, MD) was thawed in a 37°C water bath, washed
with RoosterNourish-MSC (RoosterBio, Inc., Frederick, MD) medium
and then centrifuged at 200g for 5 min. The cell pellet was suspended
in fresh RoosterNourish-MSC medium before seeding 5E3 cells/cm2
into an uncoated Nunc T175 flask (Nalge Nunc, Rochester, NY), a
Nunc T175 flask coated with 0.2 ng/cm2 fibronectin from human
plasma (Sigma-Aldrich, Missouri, USA) and a CellBIND T175 flask
(Corning Inc. NY). Flasks were topped up with medium to 35mL/flask,
then incubated at 37°C in a humidified 5% CO2 in air atmosphere.
Medium was exchanged after 2 days before harvesting on day 4 by
washing with phosphate-buffered saline (PBS) followed by incuba-
tion with 5 mL TrypLE Select (Gibco, ThermoFischer, Waltham, MA)
for 5 min at 37°C. Cell detachment was confirmed with light micros-
copy before addition of medium to quench enzyme activity.
Isolation and culture of hBM-MSCs from fresh hBM
Fresh unprocessed bone marrow aspirate obtained with informed
consent from healthy human donors was purchased from Lonza
(USA) or Caltag Medsystems (UK). Bone marrow aspirate was directly
seeded into CellBIND T175 flasks containing either RoosterNourish-
MSC medium or Dulbecco’s Modified Eagle’s medium (DMEM) sup-
plemented with 2 mmol/L GlutaMAX (Gibco, ThermoFischer, Wal-
tham, MA) and 5% or 10% Stemulate Human Platelet Lysate (HPL)
(Cook Regentec, Indianapolis, USA). Flasks were topped up to 35 mL
and incubated at 37°C in a humidified 4% O2, 5% CO2 atmosphere.
Complete medium exchange was performed at least once every
3 days as a minimum, with three Dulbecco's-PBS washes performed
before the first exchange to deplete erythrocytes and non-adhered
mononuclear cells.
Cryopreservation and thawing of hBM-MSCs
Expanded hBM-MSC colonies were harvested by washing with PBS,
then incubating with TrypLE Select for up to 10 min at 37°C. Cell detach-
ment was confirmed with light microscopy and the cells were diluted
with medium to quench enzyme activity before mixing by trituration
and transfer into sterile 50-mL centrifuge tubes. Samples were taken for
cell counting and viability assessment, and the remaining cell suspension
was pelleted using centrifugation at 200g for 5 min. The cell pellet was
suspended to freezing density of 1E6 cells/mL or 2E6 cells/mL in a freez-
ing medium containing either 2% or 10% dimethyl sulfoxide, loaded into
1.8-mL Nunc cryovials with 1 mL fill volume and allowed to equilibrate
at ambient temperature for 10 min. After equilibration, cryovials were
loaded into a Via-Freeze Research (Asymptote Ltd, UK) containing a pre-
chilled (4°C) sample block. Cryovials were held until the sample block
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at either -1°C/min or -2°C/min to a target temperature of -80°C. Frozen
cryovials were transferred to long-term storage under liquid nitrogen
vapor (<-150°C) for at least 1 week, until thawing for post-thaw culture
analysis. Cryovials containing frozen hBM-MSCs were thawed in a 37°C
water bath and the contents were diluted with 4 mL of DMEM supple-
mented with 10% Stemulate before centrifugation at 200g for 5 min. The
resulting supernatants were discarded and the cell pellets suspended
into DMEM supplemented with 10% Stemulate for culture analysis.
Culture analysis
Cell count and viability
Bone marrow aspirate samples were analysed using the Viability
and Cell Count Blood Assay on a NC-3000 (Chemometec, Denmark)
as per the manufacturer’s instructions.
Harvested hBM-MSCs were analyzed using the Viability and Cell
Count Assay as per the manufacturer’s instructions.
Assessment of cell morphology and colony morphology
Cell morphology and colony morphology were monitored daily
during hBM-MSC expansion using light microscopy to inform the
decision to proceed to cell harvesting.
Colony-forming assay
Defined volumes (100 mL to 300 mL) of bone marrow aspirate were
carefully seeded into CellBIND T25 flasks containing 5 mL of growth
medium using a pipette. Flasks were fed every 3 days and after 12 days
were washed with PBS, fixed using chilled 4% (wt/vol) paraformaldehyde
in PBS at least 30 min at room temperature. Fixed flasks were stored
chilled with parafilm covering until staining with 2% (wt/vol) toluidine
blue in PBS at room temperature for 1 h. Sequential PBS washing was
used to de-stain and dyed hBM-MSC colonies (>50 cells) were manually
counted with the aid of a light microscope.
Surface marker expression using flow cytometry
Thawed hBM-MSCs were seeded into CellBIND T25 flasks at 5E3 cells/
cm2 and cultured in 5 mL DMEM + 10% Stemulate HPL for 4 days, with a
medium exchange on day 2. Harvesting was performed using PBS wash-
ing then incubation with 1 mL TrypLE Select at 37°C for 5 min. Cells were
centrifuged at 300g for 5 min and resuspended in flow buffer (PBS con-
taining 1% Bovine Serum Albumin) and mixed with the appropriate vol-
ume of antibody, incubated for 30 min at room temperature, washed
once and analyzed using a BD FACSCanto II flow cytometer (BD Bioscien-
ces, USA) and gated against specific isotype controls. The antibody panel
applied was CD105, CD73, CD44, CD45, CD34, CD11b, CD19, HLA-DR,
CD146 melanoma cell adhesion molecule (MCAM), CD106 vascular cell
adhesion molecule (VCAM) and Stage specific embryonic antigen 4
(SSEA-4) (all BD Biosciences, USA).
Osteogenic differentiation
Thawed hBM-MSCs were seeded into Nunc 12-well plates at 1E4
cells/cm2 and cultured in 0.5 mL DMEM + 10% Stemulate HPL growth
medium for 2 days. After 2 days, one plate was cultured for an addi-
tional 24 h then sacrificed as an unstained control using 70% cold eth-
anol fixation and parafilm storage until staining. A second plate was
exchanged with MSCGo Rapid Osteogenic differentiation medium
(Biological Industries, Israel) and returned to the incubator for a fur-
ther 9 to 12 days with medium exchange every 2 to 3 days. Differenti-
ated cells were 70% ethanol fixed and both undifferentiated and
differentiated cells were stained using 2% alizarin red staining solu-
tion to detect calcium mineralization.
Outgrowth analysis
Thawed hBM-MSCs were seeded into Nunc 6-well plates at 5E3
cells/cm2 and cultured in 1 mL DMEM + 10% Stemulate HPL growthmedium for up to 4 days, with a medium exchange on day 2. Plates
were sacrificed on days 2, 3 and 4 for spent medium analysis and cell
harvesting using PBS washing followed by 0.2 mL TrypLE Select incu-
bation for 5 min at 37°C. Cell detachment was confirmed with light
microscopy and enzyme activity was quenched with growth
medium, and suspended cells were counted. Cell counts were then
used to determine growth kinetics after 2 days post-thaw recovery.
Spent medium analysis
Glucose, lactate and ammonia concentration in spent medium
samples were measured using a Cedex Bioanalyzer HT (Roche Cus-
tomBiotech, Germany) as per the manufacturer’s instructions.
Secreted vascular endothelial growth factor (VEGF) concentration in
spent medium was measured using an Invitrogen VEGF enzyme-
linked immunosorbent assay kit (ThermoFisher Scientific, UK) as per
the manufacturers’ instructions. Cell-specific production or consump-
tion rates were derived using linear regression of cumulative cell
time and concentration.
Monte Carlo simulation of autologous hBM-MSC isolation variability
The quantity of hBM-MSCs isolated can be defined by the total
nucleated cell (TNC) concentration and the percentage of nucleated
cells that form colonies on tissue culture plastic with the correct phe-
notype, multiplied by the total aspirate volume. Data of mean values
and standard deviations of TNC per milliliter and the number of h-
MSCs/mL were taken from Hernigou et al. [15] of 30 healthy human
donors, over a wide age range, with no explicit bias in data toward
any reported population. Aspirates were taken from multiple inde-
pendent sites using 10-mL syringes to aspirate 1 mL, 2 mL, 4 mL and
10 mL bone marrow samples from each patient. Figure 1A shows
how the relationship between TNC density and hBM-MSC density is
dependent on the aspirate volume.
A Monte Carlo simulation of bone marrow isolation was made in
Excel 2010 (Microsoft, UK). Cumulative normal distributions were
generated for total nucleated count (cells/mL), colony-forming units
(as a percentage of total nucleated count) and aspirate volume using
the Excel normal distribution function (NORMDIST), using mean and
standard deviations derived using data from Hernigou et al. [15],
shown in Table 1. Because 1-mL aspirations gave better hBM-MSC
yield as a function of TNC (Figure 1A), we derived mean and standard
deviation values using the 2 mL, 4 mL and 10 mL aspiration data to
avoid best-case scenarios, which are unlikely to be practical to
achieve reliably where several milliliters of aspirate may be required.
A random cumulative probability value (0 to 1) was generated with
the NORMDIST function incorporating the Excel random function
[RAND()], with minimum and maximum values (Table 1) applied to
randomly generate values from a truncated normal distribution to
avoid negative values. The Excel normal distribution inverse function
(NORMINV) was then used to return the inverse of the randomly gen-
erated cumulative probability value. Total hBM-MSCs from each simu-
lated aspiration were then determined by multiplying total nucleated
cells/mL, hBM-MSC fraction (divided by 100) and aspirate volume
together. Population doubling targets were defined as the binary loga-
rithm of the target hBM-MSC number minus the binary logarithm of
the isolated hBM-MSC number.
Results
Defining the impact of biological input variability on the manufacturing
process using Monte Carlo modelling
It is costly and potentially impractical to perform enough bone
marrow isolations to gain a statistically robust understanding of the
distribution of BM-MSC yield during a resource constrained cell ther-
apy development process. However, this information is necessary to
Figure 1. Plot (A) A scatter plot of BM-MSCs/mL and TNC count/mL as a function of aspirate volume drawn with a 10-mL syringe (raw data taken from Hernigou et al. [15]). Linear
regression lines are shown to illustrate that BM-MSC yield decreases considerably as aspiration volume increases from 1 mL to 2 mL and above. Plot (B) shows the Hernigou data
overlaid onto a dot plot of 30 000 simulated outcomes using the Monte Carlo model.
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tate rapid process development, we created a model of BM-MSC yield
distribution from literature data describing the effects of aspirate vol-
ume on target cell concentration, and population variability in target
population.
A multi-step Monte Carlo simulation was used to simulate
30 000 bone marrow aspirations using the parameters in Table 1. For
each simulation, TNCs per milliliter and the fraction of TNC that are
hBM-MSCs were independently obtained, and the resulting hBM-
MSC concentration was calculated. Total hBM-MSCs per aspiration
was then obtained by multiplying hBM-MSC concentration with a
randomly generated aspirate volume (generated from a target mean
of 5 mL, assuming a truncated normal distribution, with a minimum
2 mL and maximum 12 mL cut-off). The resulting population of total
BM-MSCs per aspirate in 30 000 simulated aspirations formed a long-
tailed distribution (Figure 2A). The number of hBM-MSCs ranged
from fewer than 250 to more than 10 000, suggesting a plausible
range approaching two orders of magnitude.
Isolated hBM-MSCs need to be expanded in vitro until a target
yield is reached that will be specific to a clinical indication. Our yield
specification was 2E7 cells (using the exemplar of an autologous cell
population intended to be combined with an implantable scaffold
material). This target included approximately 50% overage as an ini-
tial estimate of requirements for quality control and assurance test-
ing, and to account for potential losses during cell washing,
formulation and cryopreservation.
The 2E7 hBM-MSC yield target informs the number of popula-
tion doublings needed to meet this process specification given
hBM-MSC input from each simulated aspiration. These population
doublings create a further distribution representing the variability
in required proliferation to hit the target yield if a product devel-
oper used all available input material (Figure 2B). Over half (64%)
of the simulated aspirates would need 13 population doublings to
meet the harvest target, whereas 16 doublings would be neces-
sary to ensure >95% meet the harvest target. The populationTable 1
Monte Carlo model parameters.
TNC (cells/mL) CFU (%TNC) Aspirate volume (mL)
Min 2.00E+06 0 2.5
Max 8.00E+07 0.006 12
Avg 2.39E+07 0.003 5
SD 1.18E+07 0.002 2
CFU, colony-forming unit; Min, minimum; Max, maximum; Avg, average.doubling range defined by the model implies different manufac-
ture times for different inputs posing an operational challenge. A
variable manufacture time would complicate logistics, particularly
for products that lack a cryopreservation hold step. We, therefore,
adopted a strategy of determining a fixed manufacturing window
within which an acceptable proportion of material would be esti-
mated to reach the target yield.
Proliferative rate (doubling time) is the final critical parameter
determining the cell output in a fixed time window. However, differ-
ent donors are reported to have different proliferative rates further
compounding the variability in quantity of input material. To address
this, we evaluated the proportion of simulated aspirates that would
meet the 2E7 BM-MSCs harvest target within a 12- to 15-day fixed
manufacturing window as a function of both hypothetical doubling
time and aspirate volume seeded. Figure 3 shows the proportion of
runs predicted to achieve target within a range of 12 to 15 days, as
well as those exceeding the yield target before 12 days and those fail-
ing to achieve target within 15 days, with seeded aspirate volumes of
6 mL, 9 mL and 12 mL. The peak success rate (cultures achieving tar-
get in a 12- to 15-day window) is seen at a different cell doubling
time at different aspiration volumes. We would, therefore, want to
specify an aspiration volume that had a peak success rate aligned
with the average population doubling time in the donor material and
expansion process.
Establishing a reasonable window is critical as cultures that grow
too rapidly risk exhausting nutrients (e.g., glucose) or production of
excessive inhibitory metabolites (e.g., ammonia) given a standardized
feeding process targeting the average input. Similarly, cultures which
need excessive expansion time to achieve target specification may
require passaging if cell motility is insufficient to avoid dense colo-
nies and the emergence of cell aggregates during harvesting. These
more extreme cultures that fall outside the manufacturing window
may have associated quality issues and could be treated as special
cases under risk assessment.
The model outputs highlight the criticality of growth rate
when considering the probability of achieving a well-controlled
process within a specified manufacturing window. Consequently,
the Monte Carlo model enables the specification and benchmark-
ing of acceptable culture parameters (e.g., seeding volume range)
to obtain a well-defined culture system compatible with a poten-
tially variable biological input. Defining the process in this way
should allow management of hard to control process steps like
aspiration (e.g., acceptable aspirate volume ranges) to minimize
the chance of wasteful manufacturing deviations due to end har-
vest number out of specification.
Figure 2. AMonte Carlo model was run using raw data from Hernigou et al. to simulate 30 000 bone marrow isolation processes given TNC concentration, MSC percentage and aspi-
rate volume variability. Plot (A) shows a histogram of total number of hBM-MSCs isolated (assuming 100% recovery) with a 250 bin size and a lumped bin for output >10 000 for
ease of visualization. Plot (B) shows the previous histogram as a function of the minimum number of population doublings needed to obtain 2E7 cells at harvest.
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using the Monte-Carlo model
Different manufacturing materials and processes are expected to
deliver different proliferative rates. We, therefore, screened key varia-
bles to establish a process growth rate that would maximize the harvest
target to be met within a 15-day manufacturing window (for a given
aspirate volume) given the estimations obtained from the Monte Carlo
model. First, the impact of culture surface on cell proliferation and har-
vest density were evaluated. Rooster hMSCs were used in Rooster
medium with a 4-day fed-batch expansion on either Corning CellBIND
T-flasks, delta-Nunclon treated-flasks or Nunc flasks coated with fibro-
nectin. Rooster hMSCs were chosen for their availability and consistency
over fresh bonemarrow aspirates for this development step.Approximately twice as many cells were recovered at harvest
(approximately 6E4/cm2 versus 3E4/cm2) using CellBIND and fibronec-
tin-coated flasks compared with delta-Nunclon flasks (Figure 4A). Appar-
ent doubling time was shortened from 34 h1 on delta-Nunclon flasks to
26 h1 on CellBIND and fibronectin-coated flasks (Figure 4D), with
improved membrane integrity (99% versus 97%) on harvest (Figure 4C). It
was also noted that mean cell diameter was smaller in CellBIND flasks
compared with cells cultured on delta-Nunclon or fibronectin-coated
flasks (Figure 4B). These data suggest CellBIND flasks afford increased
headroom for hBM-MSC expansion per centimetre squared of the culture
surfaces evaluated, without increasing raw material qualification burden
by introducing fibronectin.
After selecting the CellBIND surface for further evaluation, a two-
stage approach was used to quickly establish a suitable
Figure 3. Predicting the proportion of autologous donor inputs that will achieve the
target yield (2E7 cells) given different doubling times: (A) 6 mL bone marrow; (B) 9 mL
bone marrow and (C) 12 mL bone marrow. Each curve represents the proportion of
simulated manufacturing runs that meet target yield within 1215 days (green curve),
meet target before 12 days (orange curve) or fail to meet target within 15 days (red
curve), as a function of growth rate. Data generated using predicted population dou-
bling target distribution of 30 000 simulated BM-MSC isolation and expansions from
bone marrow aspirates (Figure 1).
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work. Two fresh human bone marrow aspirates from healthy donors
(LOC18 001 and LOC18 002) were used to confirm the suitability of
CellBIND flasks, select an appropriate growth medium and feeding
regime, as well as to provide material to scope out a feasible cryo-
preservation process. The process specified using these studies was
then challenged with engineering runs using four different healthy
donor bone marrow aspirates from two different suppliers (LOC18
003, 004, 005 and 006), according to standard operating procedures
and data recorded in line with that required for a draft manufacturing
batch record.
Adherent cells with BM-MSC morphology were successfully iso-
lated and expanded as colonies from 3 mL LOC18 001 aspirate
directly plated into CellBIND flasks containing DMEM supplemented
with 10% or 5% Stemulate. In contrast, no colonies were isolated from
LOC18 001 aspirate when using RoosterNourish medium, with no
BM-MSCs visible by microscopy after the first wash and medium
exchange (Table 2).
DMEM-Stemulate culture in CellBind flasks supported more than
12 population doublings during a 14-day expansion under hypoxic
(4% O2) growth conditions (Table 2). Doubling time was 25.4 h1with 10% Stemulate supplementation (Table 2), consistent with the
doubling times previously established for Rooster hMSCs on CellBIND
flasks in RoosterNourish medium (Figure 4D). Around 220 hBM-MSC
colony forming units per mL aspirate were isolated, which would sat-
isfy the 2E7 BM-MSC harvest target within 15 days if at least 6 mL
were seeded into three T175 flasks. Doubling time was maintained
over serial passaging, with retention of expected cell morphology for
at least 20 in vitro population doublings under hypoxic (4% O2) cul-
ture conditions suggesting substantial proliferative headroom
(Figure 5A).
A customs delay for the second donor (LOC18 002) resulting in a
72-h shipping period, with noticeable evidence of clotting in the aspi-
rate on visual inspection. Consequently, a higher seeding volume (4
mL) was used to compensate for presumed loss of hBM-MSC yield.
Adherent cells with hBM-MSC morphology were also isolated and
expanded as colonies from 4 mL LOC18 002 aspirate directly plated
into CellBIND flasks supplemented with 10% Stemulate. While this
donor contained fewer colony-forming units than the first (71 versus
220), over 15 population doublings occurred during a 15-day expan-
sion (22 h1 to 24 h1 doubling times), resulting in enough cells in all
three flasks to meet the 2E7 harvest target (Table 2). A feed 24 h
post-seeding followed by a 3-day feed cycle without a wash was
acceptable and supported cell growth to confluence in excess of other
strategies (>6E4 cells/cm2). Doubling times were also stable over 30
populations doublings during serial passaging (Figure 5B).
The successful isolation and expansion of hBM-MSCs from both
donors established the suitability of both CellBIND flasks and Stemu-
late-supplemented DMEM fed on a 3-day feeding cycle for our candi-
date manufacturing protocol. The observed doubling times of
between 22 and 26 h would translate into more than 95% of runs suc-
cessfully meeting the harvest target within the 15-day manufacturing
window for an aspirate seeding volume range of 9 mL to 12 mL.
Both pre-engineering run donor hBM-MSCs were successfully har-
vested, cryopreserved, thawed and expanded with assessment of a
range of hMSC quality criteria (data summarized in Table 3). A screen-
ing evaluation of faster cooling rates (-2°C/min) and lower Dimethyl
Sulfoxide (DMSO) concentration (2%) were associated with greater cell
loss post-thaw. However, hBM-MSCs were still recoverable, with
thawed cells maintaining proliferative potential with comparable dou-
bling times to that observed pre-freeze. Candidate quality criteria
were assessed on thawed cells including secreted VEGF and consumed
glucose and secreted lactate (with a 1.7 stoichiometry observed). Fur-
thermore, after 4 days of post-thaw expansion, harvested cells dis-
played surface marker expression profiles consistent with the
International Society for Cellular Therapy (ISCT) criteria [17], with
>95% expression of CD105, CD73 and CD44 and <2% expression of
CD45, CD34, CD11b, CD19 and HLA-DR (Table 2). Isolated BM-MSC cul-
tures also displayed appropriate morphology and exhibited >95%
expression of CD146 (MCAM), <23% CD106 (VCAM) expression and
1620% SSEA-4 expression (Table 3). Finally, the harvested cells were
able to differentiate down an osteogenic lineage as demonstrated by
calciummineral deposition in osteogenic differentiation medium.
These results establish that direct plating of between 9 mL and
12 mL of bone marrow aspirate into 3x T175 CellBIND flasks contain-
ing DMEM + 10% Stemulate will isolate hBM-MSCs. A 3-day feed cycle
will allow hBM-MSC outgrowth with doubling times between 22 h1
and 26 h1, which provides an initial base case prediction that suffi-
cient cryopreservable hBM-MSCs to exceed a 2E7 harvest target
within a 15-day manufacturing window will be generated for more
than 95% of patients based on the Monte Carlo model.
Confirming suitability of the streamlined hBM-MSC manufacturing
process with fresh donor aspirates
To confirm that the streamlined hBM-MSC manufacturing process
was fit for purpose, we conducted four engineering runs of the
Table 2
Experimental isolation and expansion of BM-MSCs from LOC18 001 and LOC18 002 bone marrow aspirates.
Donor ID (experimental runs)
Parameter Process stage LOC18 001 LOC18 002
Bone marrow TNC count
(cells/mL)
Post-isolation 1.50E+07 2.70E+07
Bone marrow TNC count
(cells/mL)
Post-shipment 1.12E+07 1.68E+07
TNC recovery (%) Post-shipment 74.67 62.22
Shipment duration (h) Post-shipment <48 <72
Bone marrow TNC mem-
brane integrity (%)
Post-shipment 98 90
BMA seeding volume
(mL)
BM-MSC expansion 3 3 3 4 4 4
Culture duration (d) BM-MSC expansion 14 15
Culture vessel BM-MSC expansion 1 x T175 (CellBind) 1 x T175 (CellBind) 1 x T175 (CellBind) 1 x T175 (CellBind) 1 x T175
(CellBind)
1 x T175
(CellBind)
Culture medium BM-MSC expansion RoosterNourish-
MSC
DMEM + 5% Stemu-
late HPL
DMEM + 10% Ste-
mulate HPL
DMEM + 10% Stemulate HPL
Feeding strategy BM-MSC expansion 100% exchange after 1 d, then every 3 d 100% exchange after
1 d, then every 3 d
100% exchange
after 1 d, then
every 2 d
100% exchange
every 3 d
O2 (%) BM-MSC expansion 4 4
CO2 (%) BM-MSC expansion 5 5
Temperature (°C) BM-MSC expansion 37 37
BM-MSC CFU-F (colo-
nies/mL)
BM-MSC harvest 0 (failure to adhere) 224 220 71.1
BM-MSC seeding den-
sity (cells/cm2)
BM-MSC harvest ND 3.84 3.77 1.63
Harvest yield (cells/cm2) BM-MSC harvest 0 1.71E+04 3.72E+04 3.33E+04 4.79E+04 6.30E+04
Harvest yield (viable
cells/flask)
BM-MSC harvest 0 2.99E+06 6.50E+06 5.83E+06 8.38E+06 1.10E+07
BM-MSC membrane
integrity (%)
BM-MSC harvest 0 94.3 96.5 96.4 94.8 96.8
Population doublings BM-MSC harvest ND 12.13 13.25 15.34 15.9 16.32
Doubling time (h) BM-MSC harvest ND 27.7 25.4 23.47 22.64 22.06
ND, Not Detected.
Figure 4. Impact of flask surface on (A) harvest density, (B) doubling time, (C) membrane integrity and (D) mean cell diameter at harvest, after 4 days in 37°C 5% CO2 in humidified
air. Nunc FN = fibronectin-coated.
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Figure 5. Cumulative population doubling curves of (A) LOC18 001 and (B) LOC18 002 BM-MSCs expanded on CellBIND flasks in DMEM supplemented with 10% Stemulate. Solid
circles indicate data used for regression.
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ers. The process was run according to standard operating procedures
and documented using draft manufacturing batch records.
For two bone marrow aspirate donor lots (Lonza), three T175
flasks were seeded for 4 mL of bone marrow aspirate each (12 mL
total) and cultured for 12 days. For the remaining two bone marrow
aspirate donor lots (Caltag Medsystems), three T175 flasks were
seeded with 3 mL of bone marrow aspirate (9 mL total) and cultured
for 15 days. All aspirates were shipped within 48 h of collection, with
at least 75% of the expected number of nucleated cells counted on
receipt (Table 4). Furthermore, membrane integrity was >90% in all
cases, with no visible indication of clotting in any of the aspirates.
As expected, differences in isolatable colony-forming units were
observed between the donor bone marrow aspirates (range, 50400
colony-forming units/mL). Despite this variability, all engineering
runs achieved the harvest target of >2E7 cells within a 15-day limit,
with doubling times between 22 and 26 h (Table 3). The doubling
times observed were comparable with the two development runs
using DMEM+10% Stemulate on CellBIND flasks (Table 2).
Harvested hBM-MSCs from each run were successfully cryopre-
served using 10% DMSO and a -1°C/min cooling protocol, with >75%
intact cells recovered post-thaw (Table 5). Post-thaw expansion was
demonstrated in each case, with doubling times (21 to 24 h) compa-
rable or better than pre-freeze values (Table 5).
Each donor varied in terms of glucose consumption and lactate
production during post-thaw expansion, with stoichiometries rang-
ing from 1.8 to 2.4 (Table 5). However, net fluxes were consistent
with expectation (range 16 pmol/cell.d1 to 26 pmol/cell.d1) for
actively proliferating hBM-MSCs [18,19].
Population identity and purity was determined by surface marker
expression according to ISCT minimal criteria [17], with cells display-
ing >95% CD90/CD105/CD77/CD44 and <5% CD45/CD34/CD11b/
CD19/HLA-DR. Expression of CD146 (>90%), CD106 (222%) and
SSEA4 (3555%) was also detected in the population, albeit in a
donor-dependent manner (Table 5). The relevance of the cells iso-
lated from bone marrow for spinal fusion repair was also established
by confirming VEGF secretion capability (range 5.5 fg/cell.day1 to
16 fg/cell.day1) and osteogenic differentiation capability (Table 5).
Discussion
Donor and aspiration process variability complicates the specifica-
tion of bone marrow aspiration volume from patients for robust man-
ufacture of cell therapy treatments. We sought to use published
information on donor variability and stem cell isolation to facilitate
statistically informed decision-making during bioprocess design
given the limited donor data available in a constrained development
window. The objective was to generate a cell expansion process capa-
ble of achieving therapeutic cell doses with defined risk of failureaccommodating potential logistical constraints such as a target
manufacturing window.
We leveraged literature data on bone marrow isolation under
defined conditions, to model the consequences of donor variability
on relevant bioprocess parameters using a Monte Carlo approach.
Within the model boundaries, isolated cell number ranged over four
orders of magnitude, requiring up to 17 population doublings to hit
harvest target in 99% of cases. Culture time to achieve harvest target
is sensitive to mean doubling time, aspirate volume and the underly-
ing cell isolation density distribution obtained from the Monte Carlo
model. Increasing aspirate seeding volume from 6 mL to 12 mL was
only marginally effective in lowering the risk of failure to meet har-
vest target (assuming a 15-day manufacturing limit imposed for
operability reasons). Instead, the model output indicated that a cul-
ture system capable of sustaining population doubling times of
approximately 26 h or less is important to minimise failure risk <5%.
Rooster hMSCs were used to evaluate culture surface coatings, with
Corning CellBIND flasks being selected over Nunclon-Delta or fibronec-
tin-coated flasks, based on doubling rate (26 h1) and maximal cells/
cm2 at harvest. Although Rooster hMSCs are recognized to have differ-
ences to fresh hMSCs from healthy donors, their ability to proliferate
rapidly and cell size distribution were considered a reasonable enough
proxy to scope out cell surface utilization and aid the initial specifica-
tion of culture surface area requirements to be evaluated with fresh
human bone marrow aspirate from healthy donors, given the final pro-
cess would be validated with fresh cells. Two fresh human bone mar-
row aspirates were used to confirm the suitability of CellBIND flasks, to
establish the suitability of Stemulate platelet lysate as a medium sup-
plement with a reasonable feeding strategy, to establish a cryopreser-
vation process and to establish analytics suitable for in-process
monitoring and a specification for release of cryopreserved cells for
bone regeneration (e.g., VEGF secretion) [20] as an exemplar therapeu-
tic application to contextualize cell quality. Finally, we conducted four
engineering runs with fresh human bone marrow aspirate following
the process established with the aid of the Monte Carlo modelling.
These all fell within specification as expected and within the 15-day
manufacturing windowwith doubling times<26 h1.
Monte Carlo methods have been applied in several different fields
to understand probability of outcomes where prediction is difficult
due to stochastic properties of the modelled system. Consequently,
they are well suited for the prediction of cell isolation where suffi-
cient data exists of underlying statistical distributions. Establishing
an understanding of the risks donor cell supply can have on biopro-
cess design and operational risks is crucial if the resulting bioprocess
is to be robust. The Monte Carlo approach quickly enables risk-based
decision-making for bioprocess parameter setting during develop-
ment. Commercial considerations, such as fixed manufacturing win-
dow, are important for delivery of a successful therapeutic product.
Manufacturing throughput ultimately imposes restrictions on how
Table 3
Cryopreservation, post-thaw expansion and quality attributes of BM-MSCs isolated from LOC18 001 and LOC18 002 bone marrow aspirates.
Experimental runs
Parameter Process stage LOC18 001 LOC18 002
Culture medium BM-MSC expansion DMEM + 10% Stemulate HPL DMEM + 10% Stemulate HPL DMEM + 5% Stemulate HPL DMEM + 10% Stemulate HPL DMEM + 10% Stemulate HPL
BM-MSCs (cells/vial) Cryopreservation 1.00E+06 1E+06 1E+06 1.00E+06 1.00E+06
DMSO (%) Cryopreservation 2 10 10 10 2
Cooling rate (-°C/min) Cryopreservation 1 1 1 2 2
Vials Cryopreservation 1 1 1 1 1 1 6 6
BM-MSCs (cells/vial) Post-thaw 7.33E+05 1.01E+06 9.42E+05 9.82E+05 9.14E+05 8.51E+05 4.64E+05 8.24E+05
BM-MSC membrane integrity (%) Post-thaw 87.7 83.7 93.3 92.0 91.86 90.25 73.57 79.66
Viable cell recovery (%) Post-thaw 64.28 84.54 87.85 90.35 83.96 76.80 34.11 65.67
P1 culture duration (days) Post-thaw outgrowth 4 4 4 4 4
Culture medium Post-thaw outgrowth DMEM + 10% Stemulate HPL DMEM + 10% Stemulate HPL DMEM + 10% Stemulate HPL DMEM + 10% Stemulate HPL DMEM + 10% Stemulate HPL
Feeding strategy Post-thaw outgrowth No feed Fed d 2 No feed Fed d 2 No feed Fed d 2 Fed d 2 Fed d 2
Population doublings Post-thaw outgrowth 2.31 3.25 2.83 3.20 3.01 3.03 3.38 3.01
Doubling time (h) Post-thaw outgrowth 31.20 20.90 25.47 21.25 23.90 21.74 20.52 23.08
Cell-specific glucose consumption (pmo/cell.day1) Post-thaw outgrowth 25.84 ND 24.31 ND 24.42 ND 20.87 22.13
Cell-specific lactate production (pmol/cell.day1) Post-thaw outgrowth 45.39 ND 42.66 ND 41.50 ND 45.01 42.13
qLactate/qGlucose Post-thaw outgrowth 1.76 ND 1.76 ND 1.70 ND 2.16 1.90
Cell-specific ammonia production (pmol/cell.day1) Post-thaw outgrowth 4.59 ND 3.98 ND 3.01 ND 9.13 3.24
BM-MSC membrane integrity (%) Post-thaw harvest 95.50 98.80 98.30 98.40 96.00 97.90 98.79 99.63
CD90 (FITC) (%) Post-thaw harvest ND 98.35 ND ND 99.98
CD105 (PerCP-CyTM5.5) (%) Post-thaw harvest ND 99.8 ND ND 99.45
CD73 (APC) (%) Post-thaw harvest ND 99.95 ND ND 99.98
CD45/CD34/CD11b/CD19/HLA-DR (PE) (%) Post-thaw harvest ND 1.67 ND ND 1.13
CD44 (PE) (%) Post-thaw harvest ND 99.62 ND ND 92.85
SSEA-4 (PE) (%) Post-thaw harvest ND 21.49 ND ND 16.28
CD106 (VCAM) (PerCP-CyTM5.5) (%) Post-thaw harvest ND 4.68 ND ND 23.03
CD146 (MCAM) (APC) (%) Post-thaw harvest ND 95.63 ND ND 95.4
VEGF (fg/cell.day1) Post-thaw harvest 18.47 16.43 15.96 4.25 6.87
Osteogenic differentiation (alizarin red stained) Post-differentiation Pass Pass Pass Pass Pass
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Table 4
Verification of BM-MSC isolation and expansion process.
Donor ID (verification runs)
Parameter Process stage LOC18 003 LOC18 004 LOC18 005 LOC18 006
Bonemarrow TNC count (cells/mL) Post-isolation 3.62E+07 2.39E+07 1.49E+07 8.26E+06
Bonemarrow TNC count (cells/mL) Post-shipment 2.96E+07 2.30E+07 1.11E+07 6.59E+06
TNC recovery (%) Post-shipment 81.77 96.23 74.50 79.78
Shipment duration (h) Post-shipment <48 <48 <48 <48
Bone marrow TNC membrane
integrity (%)
Post-shipment 97 97.4 97.8 93.5
BMA seeding volume (mL) BM-MSC expansion 12 12 9 9
Culture duration (d) BM-MSC expansion 12 12 15 15
Culture vessel BM-MSC expansion 3 x T175 (CellBind) 3 x T175 (CellBind) 3 x T175 (CellBind) 3 x T175 (CellBind)
Culture medium BM-MSC expansion DMEM + 10% Stemulate HPL DMEM + 10% Stemulate HPL DMEM + 10% Stemulate HPL DMEM + 10% Stemulate HPL
Feeding strategy BM-MSC expansion 100% exchange every 3 d 100% exchange every 3 d 100% exchange every 3 d 100% exchange every 3 d
O2 (%) BM-MSC expansion 4 4 4 4
CO2 (%) BM-MSC expansion 5 5 5 5
Temperature (°C) BM-MSC expansion 37 37 37 37
BM-MSC CFU-F (colonies/mL) BM-MSC expansion 372.5 287.5 155 47.5
BM-MSC seeding density (cells/
cm2)
BM-MSC harvest 8.51 6.57 2.66 0.81
Harvest yield (cells/cm2) BM-MSC harvest 4.78E+04 4.01E+04 5.31E+04 4.04E+04
Harvest yield (viable cells) BM-MSC harvest 2.51E+07 2.10E+07 2.79E+07 2.12E+07
BM-MSC membrane integrity (%) BM-MSC harvest 97.7 96 98.6 98.1
Population doublings BM-MSC harvest 12.45 12.57 14.28 15.59
Doubling time (h) BM-MSC harvest 23.13 22.92 25.21 23.09
Table 5
Verification of BM-MSC cryopreservation, post-thaw expansion and quality attributes.
Donor ID (verification runs)
Parameter Process stage LOC18 003 LOC18 004 LOC18 005 LOC18 006
Culture medium BM-MSC expansion DMEM + 10% Stemulate HPL DMEM + 10% Stemulate HPL DMEM + 10% Stemulate HPL DMEM + 10% Stemulate HPL
BM-MSCs (cells/vial) Cryopreservation 1.00E+06 1.00E+06 2.00E+06 1.00E+06
DMSO (%) Cryopreservation 1.00E+01 1.00E+01 1.00E+01 1.00E+01
Cooling rate (-°C/min) Cryopreservation 1 1 1 1
Vials Cryopreservation 1 1 1 1
BM-MSCs (cells/vial) Post-thaw 9.10E+05 8.26E+05 1.78E+06 9.14E+05
BM-MSC membrane integ-
rity (%)
Post-thaw 85.18 78.90 88.43 88.59
Viable cell recovery (%) Post-thaw 7.75E-01 6.52E-01 7.87E-01 8.10E-01
P1 culture duration (days) Post-thaw outgrowth 4 4 4 4
Culture medium Post-thaw outgrowth DMEM + 10% Stemulate HPL DMEM + 10% Stemulate HPL DMEM + 10% Stemulate HPL DMEM + 10% Stemulate HPL
Feeding strategy Post-thaw outgrowth Fed d 2 Fed d 2 Fed d 2 Fed d 2
Population doublings Post-thaw harvest 3.02 3.40 3.21 3.21
Doubling time (hr) Post-thaw harvest 23.91 21.17 22.56 22.45
Cell-specific glucose con-
sumption (pmo/cell.
day1)
Post-thaw outgrowth 26.88 16.00 21.88 21.85
Cell-specific lactate produc-
tion (pmol/cell.day1)
Post-thaw outgrowth 57.46 39.11 39.46 51.70
qLactate/qGlucose Post-thaw outgrowth 2.14 2.44 1.80 2.37
Cell-specific ammonia pro-
duction (pmol/cell.day1)
Post-thaw outgrowth 9.99 8.74 10.50 15.02
BM-MSC membrane integ-
rity (%)
Post-thaw harvest 99.23 99.25 99.33 98.90
CD90 (FITC) (%) Post-thaw harvest 99.80 99.95 99.95 99.95
CD105 (PerCP-CyTM5.5) (%) Post-thaw harvest 99.65 99.65 99.45 99.45
CD73 (APC) (%) Post-thaw harvest 99.90 99.90 99.90 99.90
CD45/CD34/CD11b/CD19/
HLA-DR (PE) (%)
Post-thaw harvest 0.11 0.02 0.11 0.01
CD44 (PE) (%) Post-thaw harvest 99.80 99.90 99.90 99.90
SSEA-4 (PE) (%) Post-thaw harvest 55.80 48.39 36.66 45.65
CD106 (VCAM) (PerCP-
CyTM5.5) (%)
Post-thaw harvest 3.26 2.67 21.96 16.85
CD146 (MCAM) (APC) (%) Post-thaw harvest 95.33 94.14 94.90 89.60
VEGF (fg/cell.day1) Post-thaw harvest 13.57 5.79 5.62 6.25
Osteogenic differentiation
(alizarin red stained)
Post-differentiation Pass Pass Pass Pass
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current state of the art. Such a model provides insight into how cul-
ture duration can vary dramatically over many days between patients
with MSC-rich marrow aspirate, versus those with MSC-poor mar-
row. Appreciating these timing issues allows mitigating strategies to
be identified and deployed, for example, introducing automation to
manage flask incubation and non-invasive inspection with whole
flask microscopy to determine when to harvest. The option to per-
form passaging and additional culture period may also be adopted in
the small number of cases where a therapeutic dose is not realized in
a timely manner, or where there exist concerns about a critical qual-
ity attribute that requires sampling of cells.
A further observation is the logistical usefulness of fixed aspirate
volume and surface area for seeding, rather than seeding cells to a
target cell density (cells/mL or cells/cm2). Seeding large volumes
based on mononuclear cell density is commonly used where the end
goal is to maximize the number of hBM-MSCs obtained from a donor
[21,22]. Because isolated cell density (and percentage of stem cells
within) varies by orders of magnitude, the total surface area seeded
(and, therefore, the number of flasks) will also correspondingly vary.
Sampling, cell counting, dilution factor calculation, bone marrow
aspirate dilution, flask number determination and acquisition and
sequential flask seeding are all required to achieve a target seeding
density. Fixed surface seeding simplifies processing because cell
counts are no longer essential and minimal calculations are required
by operators. Fewer manual liquid handling steps are needed, which
minimizes contamination risk and scope for operator error. Fixing
surface area also means standardizing flask dimension, flask number
and medium requirement for each donor, simplifying resource man-
agement and cost of goods analysis. The only requirement is defini-
tion of the maximum cell yield as a function of surface area, which
can then be adjusted to provide overage for robustness in cases
where more stem cells are isolated than average. In our case, we pre-
dict a minimum of 400 cm2 would satisfy a 2E7 cell harvest target,
assuming 5E4 cells/cm2, a single 500 cm2 triple-layer flask or three
T175 flasks (525 cm2).
The model framework can be built upon to incorporate other sto-
chastic processes of relevance to bioprocessing outcomes, for exam-
ple, decay of isolatable cell yield with different shipping methods
(temperature control and duration) and disease-specific changes in
cell yield and quality. Such a modelling approach can also be adjusted
to account for different cell culture systems, where doubling time dif-
fers as a result of growth medium choice or other factors that influ-
ence culture behavior. A common example would be where human
serum is used to culture hBM-MSCS, rather than HPL. If serum was to
be used without pre-screening, it is probable that some serum lots
would result in increased frequency of inadequate proliferation rates
and, therefore, more frequent failure to achieve cell targets within a
defined manufacturing window. Using HPL instead of serum was
principally to minimize the risk of inter-donor consistency accentu-
ated by lot-specific differences [23]. Other factors, including oxygen
tension relating to the atmospheric oxygen concentration, may also
accentuate inter-donor differences in proliferation rates. Our use of
4% atmospheric oxygen concentration for hBM-MSC incubation was
based on several studies linked to relative proliferative enhancement
under these conditions compared with normal atmospheric oxygen
concentration of 20% [24,25]. Any process differences such as these
would require re-specification of the model to determine acceptable
operating parameters given the resultant performance distributions.
Similarly, although four engineering runs is not enough to confi-
dently define the real distribution of growth rate variation,
manufacturing criteria could be modified, if necessary, using the
same model as further population data was collected. If a patient
group had specific performance attributes, these would emerge and
allow modification of the model and process over time. A good data
collection and monitoring plan through product development wouldbe a critical part of a quality risk management strategy and essential
to strengthen the model and feed modifications; an obvious area for
development would be a database linking critical quality attributes
and clinical outcomes to total proliferation and terminal harvest den-
sities; once sufficient data exists to determine the clinical effect of
cells that have undergone different culture profiles, a more informed
approach can be taken to selecting aspirate volume given the quality
risk of under- or over-confluence at harvest. Such data would also
help establish which of the donors that exceed the established win-
dow may still be clinically applied, an important consideration given
the value of autologous material. It could also be used to track perfor-
mance of individual clinical centers and clinical approaches, thereby
aiding training, dissemination of best practice and reduction in donor
site variability; this is a particularly important consideration given
the reduced frequency of bone marrow aspirations and possible loss
of skills.
A potential limitation of this study is that the statistical distribu-
tions used in the modelling were obtained from a single source, com-
prising 30 individual donors. Limited richness of the underlying data
forces simplification (assuming a normal distribution) and a conser-
vative approach when assuming appropriate parameters for the con-
struction of each probability distribution. These assumptions
influence the model output and, subsequently, the estimation of the
failure rate used to define acceptable bioprocess parameter set-
points, as well as raw materials and consumables used for cell expan-
sion. It is likely the model underestimates or overestimates the real
risk of batch failure. Overestimation is preferable, as a degree of
robustness will be built into the resulting bioprocess by default, but
has an economic cost implication. Underestimation would mean
accepting a bioprocess that may fail to meet cell expansion target
within a defined expansion window. This would either require
extending the manufacturing window with additional culture time
and resource or a decrease in the operational capacity of a
manufacturing facility impacting cost of goods.
Some hMSC therapies require larger doses (>108 cells), which
could require excessive population doublings to achieve depending
on the quality of the input cell material. Because our framework
accounts for population-level proliferation rate, scalability can be
explored by changing target cell yield and evaluating the number of
population doublings needed to achieve this target reliably. Increased
risk of cell quality changes as population doubling target increases (e.
g.,>30 from healthy human donors), which means more aspirate vol-
ume will be required to achieve target within a reasonable
manufacturing window. Consequently, our framework allows scaling
questions to be appropriately defined early in development, which in
turn allows informed dialogue from clinical sites about the opera-
tional feasibility and training requirements where, for example, mul-
tiple, smaller aspirations would be preferred to maintain aspirate
quality.
In studies such as these assumptions are made to support a useful
model within the limits of available data. For example, we assume
that all cells within a population will be equally potent and make
assumptions regarding effective therapeutic dosages. Isolation and
expansion of sub-populations with ideal properties for a particular
therapeutic indication are expected to alter effective therapeutic dos-
ing as well as isolatable cell distribution. Diseased or impaired cells
may suppress therapeutic modes of action, if present in sufficient
proportions of a clinically relevant cell population. Such aspects could
be incorporated into new models using the same broad approach as
product knowledge improves.
Better quality data of cell isolation outcomes, whether it is from
well-described patient populations, different isolation methods (e.g.,
gradient separations) and different biological origins, can all be used
to make the model more informative of the real-world situation. In
this way, a cell therapy developer can progressively obtain a richer
data set over the development lifecycle from pre-clinical all the way
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not only helps in refining bioprocess parameters to control the risk of
batch failure within acceptable thresholds, but can also support dis-
crimination and troubleshooting of potentially sub-optimal results
within a network of distinct clinical sites as part of continual improve-
ment of the staff performing the stem cell isolation procedures.
Ultimately, we show the Monte Carlo approach is a useful tool for
process design and quality risk management of cell sourcing for cell
therapy process development within the logistical constraints partic-
ular to this field. The bioprocess established here as an exemplar to
highlight the model framework is suitable for a standardized cell
expansion process for personalized cell therapies for a clinically chal-
lenging orthopedic indication where the ultimate goal is integration
of manufactured cells with proprietary matrices to realize a cell-
device combination product for use in bone fusion procedures.
Finally, it recognizes that data will always be limited throughout
development and establishing a framework that can continually
incorporate new data to achieve best outcomes will be important in
maximizing success of cell therapies in cases where cell yield during
initial isolation can vary considerably.
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